Prospective, 6 Month, Open Label, Conversion Study From Mycophenolate Mofetil (MMF) to PRMYFORTIC*

Inclusion Criteria: * Received a kidney transplant at least six months * stable graft function (no increased creatinine \> 20% in the previous 4 weeks) * Receiving immunosuppressive regimen with stable dose of MMF for at least 4 weeks * Immunosuppressive regimen with a dose of MMF (dose≤ 2.0 g/day) at least 4 weeks OR C0 MMF \< 1.4 µg/ml at visit 1 OR patients receiving MMF who have GI side effects * Willing to provide written informed consent * Women of childbearing age must have a negative pregnancy test and use a medically acceptable method of contraception throughout the treatment period; * Over 18 years of age. Exclusion Criteria: * GI symptoms assumed or known not to be caused by MPA therapy; * Acute rejection episode ≤ 4 weeks prior to study enrollment; * Liver disease interfering with enterohepatic recirculation, such as active hepatitis B, active hepatitis C, autoimmune hepatitis and liver cirrhosis; * Female patients who are pregnant, lactating or of child bearing potential and not practicing an approved method of birth control; * Active bacterial, viral or fungal infection; * Presence of psychiatric illness that in the view of the investigator would interfere with study requirements; * Known sensitivity to the study drug; * Receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment.